Mongersen

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMongersen
Drug Alias Namemongersenum孟戈生mongersen蒙格生GED-0301
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMothers against decapentaplegic homolog 7 inhibitors
TargetsMothers against decapentaplegic homolog 7
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGiuliani Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelgene Corp
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A